Exelixis (EXEL) Stock Spikes on First Quarter Earnings Report

NEW YORK (TheStreet) -- Exelixis (EXEL) shares closed Friday's trading session, up 8.68% to $3.38 on heavy volume after the biotechnology company reported its first quarter earnings results after the closing bell yesterday.

The San Francisco-based company reported first quarter net income of $35.2 million, which translated to a loss of 18 cents per share, beating analysts' net loss expectations of 23 cents per share by a nickel.

The company reported first quarter revenue of $9.4 million which also topped the consensus estimate of $8.3 million.

About 13.44 million shares exchanged hands as of 4:06 p.m. ET today, compared to its average trading volume of about 2.84 million shares a day.

Exelixis is engaged in developing small molecule therapies for the treatment of cancer.

EXEL Chart EXEL data by YCharts

More from Markets

Billionaire Investor Tim Draper Explains Why Bitcoin Will Hit $250,000 in 2022

Billionaire Investor Tim Draper Explains Why Bitcoin Will Hit $250,000 in 2022

To Think a Trade War's Still Just a Threat Is the Dumbest Thing on Wall Street

To Think a Trade War's Still Just a Threat Is the Dumbest Thing on Wall Street

M&A Trends Still on Investors' Minds Despite Worries Over Tariffs -- ICYMI

M&A Trends Still on Investors' Minds Despite Worries Over Tariffs -- ICYMI

Dow Falls as U.S. Imposes Tariffs on $50 Billion of Chinese Goods

Dow Falls as U.S. Imposes Tariffs on $50 Billion of Chinese Goods

General Motors Spikes on Report It's Considering Listing Shares of Cruise Unit

General Motors Spikes on Report It's Considering Listing Shares of Cruise Unit